Purpose:
Conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of steroid-induced rosacea has rarely been explored.
Patients and methods:
We present a case of steroid-induced rosacea successfully treated with JAK inhibitor tofacitinib, with no adverse effects.
Results:
This case report of successful treatment shows a good clinical efficacy of JAK inhibitors tofacitinib in the treatment of SIR.
Conclusion:
JAK inhibitor tofacitinib may be a promising agent for the treatment with steroid-induced rosacea, especially for patients who have failed to conventional therapy.